Clinical Trials Browser

Phase 2 × iniparib × Clear all

NCT01204125 2017-03-22

SOLTI NEOPARP

Phase 2 Completed

Breast Cancer Female

NCT00813956 2016-03-17

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT01033123 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Phase 2 Completed

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01033292 2016-03-17

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 2 Completed

Hypersensitivity, Neoplasms, Ovarian Neoplasms, Recurrence

NCT01173497 2016-03-17

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Phase 2 Completed

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01045304 2014-01-14

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT00677079 2013-10-01

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

Classical hematology

Fanconi Anemia, Complementation Group D1

NCT01086254 2013-09-24

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00540358 2012-12-28

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms